What is the best way to diagnose and stage malignant pleural mesothelioma?

Size: px
Start display at page:

Download "What is the best way to diagnose and stage malignant pleural mesothelioma?"

Transcription

1 doi: /icvts Interactive CardioVascular and Thoracic Surgery 12 (2011) Best evidence topic - Thoracic oncologic What is the best way to diagnose and stage malignant pleural mesothelioma? a a b b, Imran Zahid, Sumera Sharif, Tom Routledge, Marco Scarci * a Imperial College London, South Kensington Campus, London SW7 2AZ, UK b Department of Thoracic Surgery, Guy s Hospital, Great Maze Pond, London SE1 9RT, UK Received 14 September 2010; accepted 13 October Summary A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was which diagnostic modality wcomputed tomography (CT), positron emission tomography (PET), combination PETyCT and magnetic resonance imaging (MRI)x provides the best diagnostic and staging information in patients with malignant pleural mesothelioma (MPM). Overall, 61 papers were found using the reported search, of which 14 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results are tabulated. We conclude that fluorodeoxyglucose (FDG)-PET is superior to MRI and CT but inferior to PET-CT, in terms of diagnostic specificity, sensitivity and staging of MPM. Four studies reported outcomes using FDG-PET to diagnose MPM. PET diagnosed MPM with high sensitivity (92%) and specificity (87.9%). Mean standardised uptake value (SUV) was higher in malignant than benign disease (4.91 vs. 1.41, P ). Lymph node metastases were detected with higher accuracy (80% vs. 66.7%) compared to extrathoracic disease. Three studies assessed the utility of PET-CT to diagnose MPM. Mean SUV was higher in malignant than benign disease (6.5 vs. 0.8, P-0.001). MPM was diagnosed with high sensitivity (88.2%), specificity (92.9%) and accuracy (88.9%). PET-CT had low sensitivity for stage N2 (38%) and T4 (67%) disease. CT-guided needle biopsy definitively diagnosed MPM after just one biopsy (100% vs. 9%) much more often than a blind approach. CT had a lower success rate (92% vs. 100%) than thoracoscopic pleural biopsy but was equivalent to MRI in terms of detection of lymph node metastases (Ps0.85) and visceral pleural tumour (Ps0.64). CT had a lower specificity for stage II (77% vs. 100%, P-0.01) and stage III (75% vs. 100%, P-0.01) disease compared to PET-CT. Overall, the high specificity and sensitivity rates seen with open pleural biopsy make it a superior diagnostic modality to CT, MRI or PET for diagnosing patients with MPM Published by European Association for Cardio-Thoracic Surgery. All rights reserved. Keywords: Diagnosis; Malignant mesothelioma; Fluorodeoxyglucose-positron emission tomography; Computed tomography 1. Introduction A best evidence topic in thoracic surgery was constructed according to a structured protocol. This is fully described in the ICVTS w1x. 2. Three-part question In wpatients with malignant mesotheliomax is wfdg-petx superior to wct or MRIx in terms of wdiagnostic specificity, sensitivity and tumour stagingx. 3. Clinical scenario You are at a multidisciplinary meeting and review a 61- year-old retired plumber, with past asbestos exposure, who presented with chronic cough and shortness of breath. Computed tomography (CT)-scan identified a right-sided pleural effusion with thickening of the parietal pleura and loss of volume on the affected side. You suspect it could be malignant mesothelioma but are unsure as to which *Corresponding author. Tel.: q ; fax: q address: (M. Scarci) Published by European Association for Cardio-Thoracic Surgery diagnostic modality would provide a definitive diagnosis and stage the disease accurately. You resolve to check the literature yourself. 4. Search strategy Medline search 1950 to August 2010 was performed using the OVID interface wmalignant pleural mesothelioma.mpx AND wimaging.mpx AND wdiagnosis.mpx. 5. Search outcome Sixty-one papers were found using the reported search. From these, 14 papers provided the best evidence to answer the clinical question. These are presented in Table 1. In addition, the reference list of each paper was searched. 6. Results Four studies reported outcomes using fluorodeoxyglucosepositron emission tomography (FDG-PET) to diagnose suspected malignant pleural mesothelioma (MPM). Bernard et al. w2x diagnosed MPM with high sensitivity (92%) and

2 I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) Table 1. Best evidence papers Bernard et al., (1998), Chest, Single centre experience Sensitivity 92% FDG-PET is a highly USA, w2x involving 28 patients sensitive diagnostic tool Specificity 75% for malignant Retrospective cohort study All patients underwent mesothelioma (level 2b) FDG-PET Accuracy 89% FDG-PET can Diagnosis was confirmed by Detection of lymph 12 accurately differentiate thoracoscopic biopsy (ns21), node metastases Specificity 83% between benign and pleural biopsy (ns4), Accuracy 80% malignant disease cytology (ns1), clinical follow-up (ns1) and pleural Mean SUV Malignant: 4.91"2.90 decortication (ns1) Benign: 1.41"0.63 (P ) Tumourylung ratio Malignant: 12.97"9.23 Benign: 2.69"1.31 (P ) Yamamoto et al., (2009), Single centre experience Accuracy (%) 88.2 FDG-PET effectively Nucl Med Commun, involving 33 patients distinguishes malignant Japan, w3x Sensitivity (%) 87.5 from benign pleural All patients had FDG-PET disease Retrospective cohort study Specificity (%) 87.9 (level 2b) MPM diagnosis confirmed by histopathology Mean SUVdelayed vs. Malignant disease: SUV early 9.39"7.70 vs. 7.72"6.08 SUVearly spet 60 min post (P-0.001) F-FDG injection SUVdelayedsPET 120 min post Benign disease: F-FDG injection 3.27"3.26 vs. 2.92"2.45 (PsNS) Malignant vs. benign disease: 9.39 vs (P-0.01) Mavi et al., (2009), Single centre experience over Mean SUV early Group A: 5.0"2.2 Dual time point Mol Imaging Biol, USA, seven years (% of SUV max) Group B: 4.6"1.7 FDG-PET can w4x Group C: 1.6"0.4 accurately differentiate All patients (P ) malignant mesothelioma Retrospective cohort study underwent FDG-PET from benign pleural (level 2b) (ns55) Mean SUV delayed Group A: 5.8"2.8 disease (% of SUV max) Group B: 5.3"2.0 Patients divided into: Group C: 1.4"0.3 FDG-PET could not Group A: (P ) distinguish between New diagnosis MPM (ns28) newly diagnosed MPM Group B: and long standingy Recurrent MPM (ns16) recurrent disease Group C: Benign pleural disease (ns11) Best Evidence Topic SUVearlysPET 60 min post F-FDG injection SUVdelayedsPET 90 min post F-FDG injection Flores, (2005), Lung Cancer, Single centre experience over Accuracy 98.3% FDG-PET accurately USA, w5x five years diagnoses malignant Mean SUV Overall: 6.6 (range ) mesothelioma and can Retrospective cohort study All patients underwent N0 N1 disease: 5.3"2.1 distinguish mediastinal (level 2b) FDG-PET (ns63) N2 disease: 8.6"3.4 lymph node involvement from Detection of N2 disease 78"10% localyno lymph node (area under ROC) metastases Detection of T4 Sensitivity: 19% tumours Specificity: 91% (Continued on next page)

3 256 I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) Table 1. (Continued) Detection of Accuracy: 66.7% extrathoracic disease Yildrim et al., (2009), Single centre experience over Accuracy (%) 90.3 FDG-PETyCT is a J Thorac Oncol, Turkey, three years involving 31 patients highly effective w6x Sensitivity (%) 88.2 diagnostic tool for All patients underwent malignant Retrospective cohort study FDG-PETyCT Specificity (%) 92.9 mesothelioma (level 2b) MPM diagnosis confirmed by Mean SUV Malignant: 6.5"3.4 histopathology Benign: 0.8"0.6 (P-0.001) Tan et al., (2010), Single centre experience over Sensitivity 94% FDG-PET-CT is a J Thorac Oncol, UK, four years involving 25 patients highly accurate w7x Specificity 100% diagnostic tool for All patients underwent detecting recurrence of Retrospective cohort study FDG-PET-CT for suspected Detection of MPM 88.9% mesothelioma (level 2b) disease recurrence (ns11) or recurrence surveillance (ns14) SUVmax of recurrent 8.9"4.0 (range 4.4) disease Erasmus et al., (2005), Single centre experience Determine tumour T Accuracy: 63% PET-CT can detect J Thorac Cardiovasc Surg, involving 29 patients stage Understaged disease: 29% malignant mesothelioma USA, w8x Overstaged disease: 8% but has comparatively All patients underwent low sensitivity and Retrospective cohort study FDG-PET-CT T4 disease detection Sensitivity: 67% specificity, especially (level 2b) Specificity: 93% for advanced disease Final disease staging Accuracy: 83% consisted of laproscopy" Main errors were related bronchoscopyymediastinoscopy Determine tumour N Accuracy: 35% to failure to identify stage Understaged disease: 35% transpericardial and Overstaged disease: 29% transdiaphragmatic disease N2 disease detection Sensitivity: 38% Specificity: 78% Accuracy: 59% Overall accuracy 72% Attanoos and Gibbs, (2008), Single centre experience over Definitive diagnosis on CT-guided: 100% Open pleural biopsy is Histopathology, UK, w9x seven years first biopsy Blind closed: 9% the most accurate and effective method to Retrospective cohort study Open pleural biopsy (ns21) Inadequate biopsy Blind closed: 32% obtain a pleural biopsy (level 2b) CT-guided closed-percutaneous biopsy (ns5) Biopsy specimen size Closed: range 1 15 Amongst closed Blind closed percutaneous (mm) Open: range percutaneous biopsies, a biopsy (ns36) CT-guided approach is Accuracy of open Specificity: 100% superior to a blind All patients had diffuse biopsy Sensitivity: 95% approach malignant mesothelioma Chamberlain et al., (2008), Single centre experience Success rate VACT: VACT conducted from Eur J Cardiothorac Surg, UK, involving 41 patients Overall: 66.6% the right side can w10x Right-sided approach: effectively diagnose VACT (ns15) 76.9% MPM but is associated Retrospective cohort study Conventional preoperative Left-sided approach: 0% with high (13%) (level 2b) staging (ns26) complication and high Mean operative time VACT: 71 min (range failure rates All patients had suspected 65 90) MPM due to a history of asbestos exposure and Conversion rate to VACT: 33.3% suggestive pleural biopsies video-assisted thoracoscopic surgery (VATS) (Continued on next page)

4 I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) Table 1. (Continued) Time to radical surgery VACT: 28"17 (days) Conventional: 87"56 (P-0.001) Gerbaudo et al., (2002), Single centre experience of 15 Sensitivity (%) CT: 83 (95% CI: 64 93) F-FDG-CI is a sensitive J Nucl Med, USA, w11x consecutive patients F-FDG-CI: 97 (95% CI: and accurate diagnostic 80 99) method to detect Retrospective cohort study All underwent CT followed malignant mesothelioma (level 2b) by F-FDG-CI Specificity (%) CT: 80 (95% CI: 30 98) F-FDG-CI: 80 (95% CI: F-FDG-CI has specific Diagnosis confirmed by 80 99) advantage over CT with histopathology and regards to detection of immunohistochemistry Accuracy (%) CT: 82 diffuse chest wall disease F-FDG-CI: 94 and lymph node metastases Agreement with biopsy CT: 82 (ks0.47, P-0.003) results (%) F-FDG-CI: 94 (ks0.77, P ) Detection of diffuse CT: 33% chest wall disease F-FDG-CI: 100% Detection of mediastinal CT: 75% lymph node metastases F-FDG-CI: 88% Detection of CT: 100% extrathoracic metastases F-FDG-CI: 100% Heelan et al., (1999), Single centre experience Detection of disease CT: 0.55 CT and MRI are equally AJR Am J Roentgenol, USA, involving 65 patients with invading diaphragm MR: 0.82 as effective at detecting w12x biopsy-proven malignant (area under ROC) (Ps0.01) disease involving visceral mesothelioma pleura and mediastinal Retrospective cohort study Detection of visceral CT: 0.67 lymph nodes (level 2b) All patients underwent CT pleural tumour MR: 0.58 and MR imaging (area under ROC) (Ps0.64) MR imaging is superior to CT in detection of Imaging was followed by a Detection of lymph CT: 0.49 disease invading surgical procedure: node involvement MR: 0.51 diaphragm and EPP (ns34), (area under ROC) (Ps0.85) endothoracic fascia thoracotomyqpartial pleurectomy (ns13), Detection of disease CT: 0.46 thoracotomyqbiopsy (ns13), invading endothoracic MR: 0.69 laproscopyqbiopsy (ns4), fascia (Ps0.05) supraclavicular node biopsy (area under ROC) (ns1) Groessebner et al., (1999), Single centre experience Biopsy success rate 100% CT-scan is a sensitive Eur J Cardiothorac Surg, UK, involving 25 patients imaging modality for w13x CT accuracy 92% malignant mesothelioma All patients were referred Prospective cohort study after CT-scan for confirmation Mortality rate 0 (level 1b) of MPM using VATS pleural biopsy Best Evidence Topic Nanni et al., (2004), Single centre experience Concordance between Overall stage match: 60% FDG-PET staged Cancer Biother Radiopharm, involving 15 patients PET and CT Exact TNM match: 27% malignant mesothelioma Italy, w14x more accurately than All patients underwent PET upstaged disease Two patients (13%) CT, leading to a change Retrospective cohort study FDG-PET and CT in management protocol (level 2b) PET downstaged disease Four patients (27%) in three patients (20%) MPM diagnosis confirmed by histology and mediastinoscopy Plathow et al., (2008), Single centre experience Overall accuracy (%) MRI: PETyCT is the optimal Invest Radiol, Switzerland, involving 54 patients CT: diagnostic tool for w15x PET: detection and staging of PET/CT: 100 malignant mesothelioma (Continued on next page)

5 258 I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) Table 1. (Continued) Retrospective cohort study Patients underwent MRI, CI Stage specific Stage II: PET and MRI alone are (level 2b) PET and PET/CT accuracy (%) MRI: 80 both accurate and CT: 77 sensitive diagnostic All patients had epithelial PET: 86 methods MPM PETyCT: 100 PETyCT vs. MRI: P-0.05 CT alone is inferior to PETyCT vs. CT: P-0.01 MRI, PET alone or PETyCT vs. PET: P-0.05 PETyCT as it significantly Stage III: underestimates patients MRI: 90 with stage III disease CT: 75 (P-0.05) PET: 83 PETyCT: 100 PETyCT vs. MRI: P-0.05 PETyCT vs. CT: P-0.01 PETyCT vs. PET: P-0.05 Stage IV: PET: 100 PETyCT: 100 Sensitivity and Stage II: specificity (%) MRI: 87.5 and 87.5 CT: 100 and 69.2 PET: 100 and 84.6 PETyCT: 100 and 100 Stage III: MRI: 91 and 100 CT: 75 and 100 PET: 83 and 100 PETyCT: 100 and 100 FDG-PET, fluorodeoxyglucose-positron emission tomography; SUV, standardised uptake value; MPM, malignant pleural mesothelioma; ROC, area under receiver operating curve; CT, computed tomography; VACT, video-assisted cervical thoracoscopy; F-FDG-CI, FDG-dual head gamma-camera coincidence imaging; MRI, magnetic resonance imaging; NS, not significant. specificity (75%). Malignant and benign disease were accurately distinguished by differences in mean standardised uptake value (SUV) (4.91"2.90 vs. 1.41"0.63, P ) and tumourylung ratios (12.97 vs. 2.69, P ). Lymph node metastases were detected with high accuracy (80%). Yamamoto et al. w3x observed large increases in delayed (120 min post- F-FDG injection) compared to early (60 min post- F-FDG injection) SUV measurements in malignant (7.72 vs. 9.39, P-0.001) but not in benign disease (2.92 vs. 3.27, PsNS). Similarly, Mavi et al. w4x reported lower mean SUV (1.6 vs. 5.0 vs. 4.6, P ) with benign pleural disease compared to newly diagnosed MPM and recurrent MPM, respectively. Flores w5x used FDG-PET to identify N2 disease with an accuracy of 78% and reported a higher mean SUV (8.6 vs. 5.3) than N0yN1 disease. Extrathoracic disease was identified with low accuracy (66.7%). PET was sensitive for only 19% of T4 tumours. Three studies used a combination of FDG-PET and CT to diagnose MPM. Yildrim et al. w6x identified MPM with high specificity (92.9%) and sensitivity (88.2%). Large differences were observed between the mean SUV (6.5 vs. 0.8, P-0.001) of malignant and benign disease. Tan et al. w7x showed that PET-CT identified recurrence of MPM with high accuracy (88.9%), specificity (100%) and sensitivity (94%) with a mean SUV of 8.9"4.0. Erasmus et al. w8x found FDG- PET-CT determined tumour T stage and N stage with accuracies of 63% and 35%, respectively. PET-CT understaged tumour T and N stage in 29% and 35% of patients and overstaged disease in 8% and 29% of patients, respectively. PET-CT had low sensitivity for T4 (67%) and N2 (38%) disease with most errors occurring due to failure to identify transpericardial and transdiaphragmatic disease. Two studies observed outcomes of pleural biopsy and thoracoscopy in diagnosing patients with MPM. Attanoos and Gibbs w9x compared the effectiveness of open pleural (ns21), CTguided closed (ns5) and blind closed percutaneous needle biopsies (ns5). CT-guided biopsy made a definitive diagnosis after just one biopsy (100% vs. 9%) much more often than a blind approach, which produced an inadequate sample in 32% of patients. Open pleural biopsy was 95% sensitive and 100% specific for MPM and biopsied larger tissue samples (range mm vs mm) than the closed approach. Chamberlain et al. w10x conducted videoassisted cervical thoracoscopy (VACT) (ns15) and compared it to conventional preoperative staging protocols (ns26). VACT produced a success rate of 76.9% from a right-sided approach (ns13) but a 0% success rate from a left-sided approach (ns3) due to operative difficulties. VACT greatly reduced time to radical surgery (28 vs.

6 I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) days, P-0.001) compared to conventional preoperative MPM staging protocols. Five studies compared the effectiveness of CT to other diagnostic modalities in identifying MPM. Gerbaudo et al. w11x compared CT to FDG-dual head gamma-camera coincidence imaging (F-FDG-CI). F-FDG-CI diagnosed MPM with equivalent specificity (80% vs. 80%) but greater sensitivity (97% vs. 83%) and accuracy (94% vs. 82%) than CT. There was strong agreement of F-FDG-CI (94%, ks0.77, P ) and CT (82%, ks0.47, P-0.003) with pleural biopsy results. F-FDG-CI detected diffuse chest wall disease (100% vs. 33%) and mediastinal lymph node metastases (88% vs. 75%) more accurately than CT. Heelan et al. w12x compared CT with magnetic resonance imaging (MRI) in 65 patients. With regards to areas under receiver operating curves (ROC), CT was equivalent to MRI in terms of detection of lymph node metastases (0.49 vs. 0.51, Ps0.85) and visceral pleural tumour (0.67 vs. 0.58, Ps0.64) but inferior to MRI at detecting disease invading the diaphragm (0.55 vs. 0.82, Ps0.01) and endothoracic fascia (0.46 vs. 0.69, Ps0.05). Grossebner et al. w13x analysed 25 patients and showed that CT had a lower success rate (92% vs. 100%) than thoracoscopic pleural biopsy. Nanni et al. w14x compared FDG-PET with CT and reported high concordance rates (60%) between the two modalities. PET upstaged disease in 13% and downstaged disease in 27% of patients, which resulted in a change in the management protocol of 20% of patients. Plathow et al. w15x compared diagnostic utility of PET-CT with CT, PET and MRI in 54 patients. PET-CT had a higher accuracy than CT, PET and MRI for stage II (100% vs. 77% vs. 86% vs. 80%, P-0.01) and stage III (100% vs. 75% vs. 83% vs. 90%, P-0.01) tumours. CT demonstrated much lower sensitivities (75% vs. 91% vs. 83% vs. 100%) at detecting MPM than MRI, PET and PET-CT, respectively. 7. Clinical bottom line There are many diagnostic modalities to identify patients with malignant mesothelioma. Currently there is no consensus as to which single modality should be used to confirm diagnosis prior to surgery. The studies above have shown that PET-CT is superior to FDG-PET, MRI and CT in terms of specificity and sensitivity of disease detection and staging of MPM. However, surgical pleural biopsy still provides the most accurate definitive diagnosis but is a more invasive procedure than PET-CT. References w1x Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac Surg 2003;12: w2x Bernard F, Sterman D, Smith RJ, Kaiser LR, Albeda SM, Alavi A. Metabolic Imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998;9: w3x Yamamoto Y, Kameyama R, Togami T, Kimura N, Ishikawa S, Yamamoto Y, Nishiyama Y. Dual time point FDG PET for evaluation of malignant pleural mesothelioma. Nucl Med Commun 2009;1: w4x Mavi A, Basu S, Cermik TF, Urhan M, Bathaii M, Thiruvenkatasamy D, Houseni M, Dadparvar S, Alavi A. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol 2009;5: w5x Flores R. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;7:S27 S32. w6x Yildrim H, Metintas M, Entok E, Ak G, Ak I, Dundak E, Erginel S. Clinical value of fluorodeoxyglucose-positron emission tomographyycomputed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease. J Thorac Oncol 2009;12: w7x Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L. Role of integrated -fluorodeoxyglucose positron emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol 2010;3: w8x Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed-tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005;6: w9x Attanoos RL, Gibbs AR. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology 2008;9: w10x Chamberlain MH, Fareed K, Nakas A, Martin-Ucar AE, Waller DA. Videoassisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant mesothelioma. Eur J Cardiothorac Surg 2008;8: w11x Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with F- FDG Dual Head Gamma-Camera coincidence imaging: comparison with histopathology. J Nucl Med 2002;9: w12x Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999;4: w13x Grossebner MW, Arifi AA, Goddard M, Ritchie AJ. Mesothelioma VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg 1999;12: w14x Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, Marengo M, Boschi S, Franchi R, Martoni A, Monetti N, Fanti S. Role of F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm 2004;4: w15x Plathow C, Staab A, Schmaehl A, Aschoff P, Zuna I, Pfannenberg C, Peter SH, Eschmann S, Klopp M. Computed tomography, positron emission tomographyycomputed tomography and magnetic resonance imaging for staging of limited pleural mesothelioma. Invest Radiol 2008; 10: Best Evidence Topic

Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?

Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? doi:10.1510/icvts.2010.255901 Interactive CardioVascular and Thoracic Surgery 12 (2011) 806 811 www.icvts.org Best evidence topic - Thoracic oncologic Does positron emission tomography offer prognostic

More information

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant

More information

Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?

Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma? doi:10.1510/icvts.2010.256271 Interactive CardioVascular and Thoracic Surgery 12 (2011) 812 817 www.icvts.org Best evidence topic - Thoracic oncologic Is pleurectomy and decortication superior to palliative

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

PET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1. Jonathan C. Daniel 2. Kenneth S.

PET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1. Jonathan C. Daniel 2. Kenneth S. PET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1 Jonathan C. Daniel 2 Kenneth S. Knox 1 Kathleen Williams 1 Departments of Medicine 1 and Surgery 2, University

More information

PET/CT in Lung Cancer

PET/CT in Lung Cancer PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

The Need for Accurate Lung Cancer Staging

The Need for Accurate Lung Cancer Staging The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives

More information

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

More information

PET/CT Imaging in Lung Cancer

PET/CT Imaging in Lung Cancer PET/CT Imaging in Lung Cancer Mylene T. Truong, MD Mylene T. Truong M.D. Objectives To discuss the role of PET/CT in the staging of lung cancer To review the recommendations from American Society of Clinical

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Use of imaging in the management of malignant pleural mesothelioma

Use of imaging in the management of malignant pleural mesothelioma Clinical Radiology (2005) 60, 1237 1247 REVIEW Use of imaging in the management of malignant pleural mesothelioma R.E. Benamore a, M.J. O Doherty b, J.J. Entwisle a, * a Department of Radiology, University

More information

Staging algorithm for diffuse malignant pleural mesothelioma

Staging algorithm for diffuse malignant pleural mesothelioma doi:10.1510/icvts.2009.213611 Interactive CardioVascular and Thoracic Surgery 10 (2010) 185 189 report - Pulmonary Staging algorithm for diffuse malignant pleural mesothelioma a, a a b c Marcin Zieliński

More information

Lung Cancer: Practical Application of Imaging In Determining Resectability. Jeremy J. Erasmus, M. D.

Lung Cancer: Practical Application of Imaging In Determining Resectability. Jeremy J. Erasmus, M. D. Lung Cancer: Practical Application of Imaging In Determining Resectability Jeremy J. Erasmus, M. D. 62 year old man with a superior sulcus tumor. Which of the following precludes surgical resection in

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Neoplasms of the LUNG and PLEURA

Neoplasms of the LUNG and PLEURA Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:

More information

Malignant pleural mesothelioma: outcome of limited surgical management

Malignant pleural mesothelioma: outcome of limited surgical management Interactive Cardiovascular and Thoracic Surgery 2 (2003) 30 34 Institutional review Thoracic general Malignant pleural mesothelioma: outcome of limited surgical management Peter G. Phillips a, George Asimakopoulos

More information

Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma

Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma 11 Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma Tatsuo Kimura, Shinzoh Kudoh and Kazuto Hirata Department of Respiratory Medicine, Graduate School of Medicine Osaka City University

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

International Journal of Case Reports in Medicine

International Journal of Case Reports in Medicine International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon

More information

Understanding Pleural Mesothelioma

Understanding Pleural Mesothelioma Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to

More information

Malignant pleural mesothelioma is a rare primary neoplasm,

Malignant pleural mesothelioma is a rare primary neoplasm, Assessment of Malignant Pleural Mesothelioma with F-FDG Dual-Head Gamma-Camera Coincidence Imaging: Comparison with Histopathology Victor H. Gerbaudo, PhD 1 ; David J. Sugarbaker, MD 2 ; Scott Britz-Cunningham,

More information

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing

More information

Assessment of 18 F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases

Assessment of 18 F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases Eur Respir J 2004; 24: 814 821 DOI: 10.1183/09031936.04.00004504 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 Assessment of 18 F-fluorodeoxyglucose

More information

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC MESOTHELIOMA Not Just a Late Night Commercial Graciela Hoal, RN, MSN, ACNP-BC Saturday Session Thoracic Surgery Nurse Practitioner Greater Los Angeles Veteran Affairs Objectives Course Objectives: Discuss

More information

Sternotomy and removal of the tumor

Sternotomy and removal of the tumor Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a

More information

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Radiologic Assessment of Mesothelioma

Radiologic Assessment of Mesothelioma 28 Radiologic Assessment of Mesothelioma Samuel G. Armato III, Heber MacMahon, Geoffrey R. Oxnard, Charles L. Croteau, and Nicholas J. Vogelzang Imaging plays an essential role in the diagnosis, staging,

More information

Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans

Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans M. Phillips, S.F. Barrington, D.L.G. Hill, P.K. Marsden 1 Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans Michael Phillips 1 Michael.Phillips.1@city.ac.uk Sally F.

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Does PET Scan change NSCLC management

Does PET Scan change NSCLC management Does PET Scan change NSCLC management V. Ninane, Bordet and Saint-Pierre Hospitals, Brussels, Belgium 1 Positron emission tomography imaging of structures based on the fact that they concentrate specific

More information

The Proposed New International TNM Staging System for Malignant Pleural Mesothelioma: Application to Imaging

The Proposed New International TNM Staging System for Malignant Pleural Mesothelioma: Application to Imaging 323.....:. #{149} :. #{149}..: #{149}. #{149}. :- : Received June 22, 1995; accepted after revision September 12, 1995. 1 Department of Radiology, Duke University Medical Center, Box 3808, Dunham, NC 2771

More information

Imaging of pleural and chest wall tumors

Imaging of pleural and chest wall tumors Thorac Surg Clin 14 (2004) 15 23 Imaging of pleural and chest wall tumors Michael J. Weyant, MD a, Raja M. Flores, MD a,b, * a Cardiothoracic Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York

More information

Management of mesothelioma

Management of mesothelioma Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)

More information

PET/CT for Melanoma. Sarajevo (Bosnia & Hercegovina) Wednesday, June :40 10:20

PET/CT for Melanoma. Sarajevo (Bosnia & Hercegovina) Wednesday, June :40 10:20 Sarajevo (Bosnia & Hercegovina) Wednesday, June 18 2014 09:40 10:20 PET/CT for Melanoma The Trundholm Sun Chariot, anterior view app 1350 BC The National Museum of Denmark, Copenhagen 54 x 35 x 29 cm (width,

More information

Thoracic 18F-FDG PETCT

Thoracic 18F-FDG PETCT Thoracic 18F-FDG PETCT RAD Magazine, 41, 482, 13-16 Dr Allanah arker Specialist registrar radiology Dr Nagmi Qureshi Consultant cardiothoracic radiologist Papworth Hospital, Cambridge email: allanahbarker@nhs.net

More information

Recommendations for the Reporting of Pleural Mesothelioma

Recommendations for the Reporting of Pleural Mesothelioma Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports

More information

False positive PET in lymphoma

False positive PET in lymphoma False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)

More information

Asbestos and your lungs

Asbestos and your lungs This information describes what asbestos is and the lung conditions that are caused by exposure to it. It also includes information about what to do if you have been exposed to asbestos, and the benefits

More information

Mesothelioma in the UK

Mesothelioma in the UK Mesothelioma in the UK Liz Darlison Mesothelioma UK The National Macmillan Mesothelioma Resource Centre June 2010 Mesothelioma Applied Research Foundation - 2010 www.curemeso.org Contents Size of Mesothelioma

More information

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200 GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung

More information

P L E U R A L M E S O T H E L I O M A

P L E U R A L M E S O T H E L I O M A For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER

NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed

More information

PET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection

PET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends

More information

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1

Mesothelioma. 1995-2013, The Patient Education Institute, Inc. www.x-plain.com ocft0101 Last reviewed: 03/21/2013 1 Mesothelioma Introduction Mesothelioma is a type of cancer. It starts in the tissue that lines your lungs, stomach, heart, and other organs. This tissue is called mesothelium. Most people who get this

More information

Role of FDG PET and PET/CT Imaging in Indeterminate Pulmonary Nodules and Lung Cancer

Role of FDG PET and PET/CT Imaging in Indeterminate Pulmonary Nodules and Lung Cancer Role of FDG PET and PET/CT Imaging in Indeterminate Pulmonary Nodules and Lung Cancer Dominique Delbeke, MD, PhD Vanderbilt University Medical Center Nashville, Tennessee Congreso Chileno de Medicina Nuclear,

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma

Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma European Review for Medical and Pharmacological Sciences Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma A. ABAKAY 1, H. KOMEK 2, O. ABAKAY

More information

Invasive Staging for NSCLC. Allan Pickens, MD Assistant Professor of Surgery Section of Thoracic Surgery Emory University

Invasive Staging for NSCLC. Allan Pickens, MD Assistant Professor of Surgery Section of Thoracic Surgery Emory University Invasive Staging for NSCLC Allan Pickens, MD Assistant Professor of Surgery Section of Thoracic Surgery Emory University Presentation 1600 1400 1200 1000 800 600 400 200 0 IA IB IIA IIB IIIA IIIB IV Stage

More information

Plueral Malignancy: Radiologic-pathologic

Plueral Malignancy: Radiologic-pathologic Plueral Malignancy: Radiologic-pathologic Correlation Ritu R. Gill, MD Pleural Malignancies: Radiologic-Pathologic Correlation Ritu R Gill MD Brigham and Women s Hospital Boston, Massachusetts Pleural

More information

Recommendations for cross-sectional imaging in cancer management, Second edition

Recommendations for cross-sectional imaging in cancer management, Second edition www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who

More information

Diagnostic Imaging and workup of Malignant Pleural Mesothelioma.

Diagnostic Imaging and workup of Malignant Pleural Mesothelioma. Diagnostic Imaging and workup of Malignant Pleural Mesothelioma. A pictorial essay Luciano Cardinale, Francesco Ardissone*, Dario Gned, Nicola Sverzellati**, Edoardo Piacibello, Andrea Veltri Department

More information

Multidisciplinary discussion of: Early staged NSCLC

Multidisciplinary discussion of: Early staged NSCLC Multidisciplinary discussion of: Early staged NSCLC 2 different classes of patients Stage IIIA pt2pn2 Stage IIB pt3pn0 2 different classes of patients 50% 40% 30% 20% 10% 3y survival 50% 40% 30% 20% 10%

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma

Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma Supported by: Asbestos Diseases Research Institute 2013 Authors: Organising Committee Publisher: Asbestos Diseases Research

More information

Case Report: Whole-body Oncologic Imaging with syngo TimCT

Case Report: Whole-body Oncologic Imaging with syngo TimCT Case Report: Whole-body Oncologic Imaging with syngo TimCT Eric Hatfield, M.D. 1 ; Agus Priatna, Ph.D. 2 ; John Kotyk, Ph.D. 1 ; Benjamin Tan, M.D. 1 ; Alto Stemmer 3 ; Stephan Kannengiesser, Ph.D. 3 ;

More information

Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database

Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database Featured Article Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database Valerie W. Rusch 1, Dorothy Giroux 2 1 Memorial Sloan-Kettering Cancer Center, New

More information

Morphologic and functional imaging of malignant pleural mesothelioma

Morphologic and functional imaging of malignant pleural mesothelioma European Journal of Radiology 64 (2007) 356 366 Review Morphologic and functional imaging of malignant pleural mesothelioma Masaki Yamamuro, Victor H. Gerbaudo, Ritu R. Gill, Francine L. Jacobson, David

More information

Surgeons Role in Symptom Management. A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND

Surgeons Role in Symptom Management. A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND Surgeons Role in Symptom Management A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND Conditions PLEURAL Pleural effusion Pneumothorax ENDOBRONCHIAL Haemoptysis

More information

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,

More information

Malignant Pleural Mesothelioma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

Malignant Pleural Mesothelioma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration http://dx.doi.org/10.4046/trd.2013.74.2.74 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:74-78 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights

More information

What is Mesothelioma?

What is Mesothelioma? What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and

More information

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,

More information

Treatment of mesothelioma in Bloemfontein, South Africa

Treatment of mesothelioma in Bloemfontein, South Africa European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Date Guideline Created: April 2013 Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1.

More information

Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma

Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,

More information

Mesothelioma: Questions and Answers

Mesothelioma: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Lung cancer forms in tissues of the lung, usually in the cells lining air passages.

Lung cancer forms in tissues of the lung, usually in the cells lining air passages. Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Pre-workshop exercise

Pre-workshop exercise Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please

More information

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,

More information

Primary pleural squamous cell carcinoma misdiagnosed as localized mesothelioma: a case report and review of the literature

Primary pleural squamous cell carcinoma misdiagnosed as localized mesothelioma: a case report and review of the literature Lin et al. Journal of Cardiothoracic Surgery 2013, 8:50 CASE REPORT Open Access Primary pleural squamous cell carcinoma misdiagnosed as localized mesothelioma: a case report and review of the literature

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases Original Article Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases William G. Richards, PhD 1,2 ; John J. Godleski, MD 2,3 ; Beow Y.

More information

Mesothelioma Understanding your diagnosis

Mesothelioma Understanding your diagnosis Mesothelioma Understanding your diagnosis Mesothelioma Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount of

More information

Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?

Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent? Interactive CardioVascular and Thoracic Surgery Advance Access published November 21, 2012 Interactive CardioVascular and Thoracic Surgery (2012) 1 7 doi:10.1093/icvts/ivs465 ORIGINAL ARTICLE Multimodal

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Mesothelioma What is malignant mesothelioma? Malignant mesothelioma is a cancer that starts in cells in the linings of certain parts of the body, especially in the linings of the chest or abdomen.

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

Magnetic resonance imaging for staging of non-small-cell lung cancer technical advances and unmet needs

Magnetic resonance imaging for staging of non-small-cell lung cancer technical advances and unmet needs Editorial Magnetic resonance imaging for staging of non-small-cell lung cancer technical advances and unmet needs Gregor Sommer, Bram Stieltjes Clinic of Radiology and Nuclear Medicine, University of Basel

More information

Primary -Benign - Malignant Secondary

Primary -Benign - Malignant Secondary TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

More than 2,500 people are diagnosed with mesothelioma in the UK each year.

More than 2,500 people are diagnosed with mesothelioma in the UK each year. This information is an extract from the booklet Understanding mesothelioma. You may find the full booklet helpful. We can send you a free copy see page 5. Contents Introduction Pleural mesothelioma Peritoneal

More information

HERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments

HERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments Table of Contents Commenters... 1 Public Comments... 2 References Provided by Commenters... 6 Commenters Identification Stakeholder A Medical Imaging & Technology Alliance (MITA), Arlington, VA [Submitted

More information

Mesothelioma and Asbestos

Mesothelioma and Asbestos CANCER INFORMATION FACTSHEET Mesothelioma and Asbestos The information in this factsheet will help you to understand more about mesothelioma. It is an agreed view on this cancer by medical experts. We

More information

Malignant Pleural Mesothelioma. NCCN Guidelines for Patients

Malignant Pleural Mesothelioma. NCCN Guidelines for Patients Malignant Pleural Mesothelioma NCCN Guidelines for Patients Presented with support from the national law firm of Baron & Budd Also available at NCCN.com About this booklet Its purpose Learning that you

More information

Patterns of nodal spread in thoracic malignancies

Patterns of nodal spread in thoracic malignancies Patterns of nodal spread in thoracic malignancies Poster No.: C-0977 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors: R. dos Santos, M. Duarte, J. Alpendre, J. Castaño, Z. Seabra, Â.

More information

Evolution of Staging in Lung Cancer

Evolution of Staging in Lung Cancer AATS Annual Meeting, Toronto, 2014. General Thoracic Session. Evolution of Staging in Lung Cancer Peter Goldstraw, Honorary Consultant Thoracic Surgeon, Royal Brompton Hospital, Emeritus Professor of Thoracic

More information